Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

被引：0
|
作者：
Wu, Y. -L. [1 ,2 ]
Sequist, L. V. [3 ,4 ]
Schuler, M. [5 ]
Yamamoto, N. [6 ]
Zhou, C. [7 ]
Hu, C. -P. [8 ]
O'Byrne, K. [9 ,10 ]
Hirsh, V. [11 ]
Mok, T. [12 ]
Zazulina, V. [13 ]
Yang, J. C. -H. [14 ,15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Univ Hosp Essen, Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[6] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[7] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
[8] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[9] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld 4102, Australia
[10] Queensland Univ Technol, Brisbane, Qld 4001, Australia
[11] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[12] Chinese Univ Hong Kong, State Key Lab South China, Hong Kong Canc Inst, Hong Kong, Hong Kong, Peoples R China
[13] Boehringer Ingelheim Ltd UK, Med, Bracknell, Berks, England
[14] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
445P
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [41] Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm plus NSCLC
    Schuler, M.
    Yang, J. C.
    Sequist, L.
    Wu, Y.
    Zhou, C.
    Geater, S.
    Mok, T.
    Tan, E.
    Hu, C.
    Yamamoto, N.
    Feng, J.
    O'Byrne, K.
    Lu, S.
    Hirsh, V.
    Huang, Y.
    Ellis, S.
    Samuelsen, C.
    Marten, A.
    Fan, J.
    Park, K.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2210 - S2210
  • [42] LUX-LUNG 3: A RANDOMIZED, OPEN-LABEL, PHASE III STUDY OF AFATINIB VS. PEMETREXED AND CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG HARBORING EGFR ACTIVATING MUTATIONS
    O'Byrne, Ken
    Schuler, Martin
    Yamamoto, Nobuyuki
    Hirsh, Vera
    Mok, Tony
    Massey, Dan
    Zazulina, Victoria
    Shahidi, Mehdi
    Sequist, Lecia
    Yang, James
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S102 - S102
  • [43] Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8)
    Morabito, A.
    Brandes, A. A.
    Sibau, A.
    Ciuffreda, L.
    Favaretto, A.
    Cappuzzo, F.
    Santoro, A.
    Vasile, E.
    Brighenti, M.
    Ferrau, F.
    Giordano, P.
    Tiseo, M.
    Soria, J.
    Felip, E.
    Lu, S.
    Goss, G. D.
    Gadgeel, S.
    Georgoulias, V.
    Chand, V. K.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 73
  • [44] LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
    Yang, James Chih-Hsin
    Schuler, Martin H.
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth John
    Hirsh, Vera
    Mok, Tony
    Geater, Sarayut Lucien
    Orlov, Sergey V.
    Tsai, Chun-Ming
    Boyer, Michael J.
    Su, Wu-Chou
    Bennouna, Jaafar
    Kato, Terufumi
    Gorbunova, Vera
    Lee, Ki Hyeong
    Shah, Riyaz N. H.
    Massey, Dan
    Lorence, Robert M.
    Shahidi, Mehdi
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
    Schuler, M.
    Paz-Ares, L.
    Sequist, L. V.
    Tan, E. H.
    Mok, T.
    Hirsh, V.
    O'Byrne, K.
    Zhang, L.
    Yamamoto, N.
    Boyer, M.
    Shah, R.
    Bennouna, J.
    Dickgreber, N. J.
    De Greve, J.
    Love, J.
    Maerten, A.
    Fan, J.
    Ehrnrooth, E.
    Park, K.
    Yang, J. C. H.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S176 - S177
  • [46] LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations
    Geater, Sarayut Lucien
    Zhou, Caicun
    Hu, Cheng-Ping
    Feng, Ji Feng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Shi, Jian Hua
    Lee, Kye Young
    Massey, Dan
    Lungershausen, Juliane
    Shi, Yang
    Zazulina, Victoria
    Wu, Yi Long
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] LUX-Lung 7: A Phase lib, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
    Park, K.
    Tan, E. -H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J.
    Mok, T.
    Kim, M.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S118
  • [48] First-line afatinib in patients with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): analysis of long-term responders (LTRs) in the LUX-Lung 3, 6 and 7 trials
    Schuler, M.
    Paz-Ares, L.
    Sequist, L. V.
    Sebastian, M.
    Wu, Y. -L.
    Geater, S. L.
    Maerten, A.
    Fan, J.
    Park, K.
    Yang, J. C. -H.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 172 - 172
  • [49] LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung
    Wu, Yi-Long
    Zhou, Caicun
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Shi, Jian Hua
    Lee, Kye Young
    Massey, Dan
    Shi, Yang
    Chen, JiongJie Jack
    Zazulina, Victoria
    Geater, Sarayut L.
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [50] AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8), A PHASE III GLOBAL TRIAL
    Goss, G. D.
    Felip, E.
    Cobo, M.
    Lu, S.
    Georgoulias, V.
    Ardizzoni, A.
    Gadgeel, S.
    Wang, B.
    Chand, V. K.
    Soria, J. -C.
    ANNALS OF ONCOLOGY, 2015, 26
12345